Song ZJ, Reitman ZJ, Ma ZY, Chen JH, Zhang QL, Shou XF, Huang CX, Wang YF, Li SQ, Mao Y, Zhou LF, Lian BF, Yan H, Shi YY, Zhao Y. The genome-wide mutational landscape of pituitary adenomas.Cell Res. 2016 Nov;26(11):1255-1259. doi: 10.1038/cr.2016.114. Epub 2016 Sep 27. PubMed PMID: 27670697; PubMed Central PMCID: PMC5099864.
Zhang L, Chen LH, Wan H, Yang R, Wang Z, Feng J, Yang S, Jones S, Wang S, Zhou W, Zhu H, Killela PJ, Zhang J, Wu Z, Li G, Hao S, Wang Y, Webb JB, Friedman HS, Friedman AH, McLendon RE, He Y, Reitman ZJ, Bigner DD, Yan H. Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas.Nat Genet. 2014 Jul;46(7):726-30. doi: 10.1038/ng.2995. Epub 2014 Jun 1. PubMed PMID: 24880341; PubMed Central PMCID: PMC4073211.
Killela PJ, Pirozzi CJ, Reitman ZJ, Jones S, Rasheed BA, Lipp E, Friedman H, Friedman AH, He Y, McLendon RE, Bigner DD, Yan H. The genetic landscape of anaplastic astrocytoma.Oncotarget. 2014 Mar 30;5(6):1452-7. doi: 10.18632/oncotarget.1505. PubMed PMID: 24140581; PubMed Central PMCID: PMC4039223.
Killela PJ, Pirozzi CJ, Healy P, Reitman ZJ, Lipp E, Rasheed BA, Yang R, Diplas BH, Wang Z, Greer PK, Zhu H, Wang CY, Carpenter AB, Friedman H, Friedman AH, Keir ST, He J, He Y, McLendon RE, Herndon JE 2nd, Yan H, Bigner DD. Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.Oncotarget. 2014 Mar 30;5(6):1515-25. doi: 10.18632/oncotarget.1765. PubMed PMID: 24722048; PubMed Central PMCID: PMC4039228.
Killela PJ*, Reitman ZJ*, Jiao Y*, Bettegowda C*, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, Mandahl N, Meeker AK, Mertens F, Netto GJ, Rasheed BA, Riggins GJ, Rosenquist TA, Schiffman M, Shih IeM, Theodorescu D, Torbenson MS, Velculescu VE, Wang TL, Wentzensen N, Wood LD, Zhang M, McLendon RE, Bigner DD, Kinzler KW, Vogelstein B, Papadopoulos N, Yan H. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6021-6. doi: 10.1073/pnas.1303607110. Epub 2013 Mar 25. PubMed PMID: 23530248; PubMed Central PMCID: PMC3625331.
Bettegowda C, Agrawal N, Jiao Y, Wang Y, Wood LD, Rodriguez FJ, Hruban RH, Gallia GL, Binder ZA, Riggins CJ, Salmasi V, Riggins GJ, Reitman ZJ, Rasheed A, Keir S, Shinjo S, Marie S, McLendon R, Jallo G, Vogelstein B, Bigner D, Yan H, Kinzler KW, Papadopoulos N. Exomic sequencing of four rare central nervous system tumor types.Oncotarget. 2013 Apr;4(4):572-83. doi: 10.18632/oncotarget.964. PubMed PMID: 23592488; PubMed Central PMCID: PMC3720605.
Reitman ZJ, Choi BD, Spasojevic I, Bigner DD, Sampson JH, Yan H. Enzyme redesign guided by cancer-derived IDH1 mutations.Nat Chem Biol. 2012 Nov;8(11):887-9. doi: 10.1038/nchembio.1065. Epub 2012 Sep 23. PubMed PMID: 23001033; PubMed Central PMCID: PMC3487689.
Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, Rodriguez FJ, Rosemberg S, Oba-Shinjo SM, Nagahashi Marie SK, Bettegowda C, Agrawal N, Lipp E, Pirozzi C, Lopez G, He Y, Friedman H, Friedman AH, Riggins GJ, Holdhoff M, Burger P, McLendon R, Bigner DD, Vogelstein B, Meeker AK, Kinzler KW, Papadopoulos N, Diaz LA, Yan H. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.Oncotarget. 2012 Jul;3(7):709-22. doi: 10.18632/oncotarget.588. PubMed PMID: 22869205; PubMed Central PMCID: PMC3443254.
Reitman ZJ, Olby NJ, Mariani CL, Thomas R, Breen M, Bigner DD, McLendon RE, Yan H. IDH1 and IDH2 hotspot mutations are not found in canine glioma.Int J Cancer. 2010 Jul 1;127(1):245-6. doi: 10.1002/ijc.25017. PubMed PMID: 19877121; PubMed Central PMCID: PMC3498760.
Reitman ZJ, Parsons DW, Yan H. IDH1 and IDH2: not your typical oncogenes.Cancer Cell. 2010 Mar 16;17(3):215-6. doi: 10.1016/j.ccr.2010.02.024. PubMed PMID: 20227034; PubMed Central PMCID: PMC4467912.